Correction: Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study

Detalles Bibliográficos
Autores principales: Bekker, Pirow, Dairaghi, Daniel, Seitz, Lisa, Leleti, Manmohan, Wang, Yu, Ertl, Linda, Baumgart, Trageen, Shugarts, Sarah, Lohr, Lisa, Dang, Ton, Miao, Shichang, Zeng, Yibin, Fan, Pingchen, Zhang, Penglie, Johnson, Daniel, Powers, Jay, Jaen, Juan, Charo, Israel, Schall, Thomas J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319730/
https://www.ncbi.nlm.nih.gov/pubmed/30608991
http://dx.doi.org/10.1371/journal.pone.0210593

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319730/
https://www.ncbi.nlm.nih.gov/pubmed/30608991
http://dx.doi.org/10.1371/journal.pone.0210593

Ejemplares similares